← All organizations
Highest phase reached
Phase 3
First clinical trial
Oct 1, 2016Last known activity
Feb 27, 2026
Timeline
2000s
- Jun 1, 2009
Ascentage Pharma Group Inc.— Founded
Drugs by trial phase (39 distinct, 56 trials)
Phase 3 (10 own, 0 via acquisition)
Phase 2 (23 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Carcinoma, Non-Small-Cell Lung
- Gastrointestinal Stromal Tumors
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Accelerated Phase
- Leukemia, Myeloid, Acute
- Leukemia, Prolymphocytic
- Leukemia, Prolymphocytic, T-Cell
- Lung Neoplasms
- Lymphoma
- Lymphoma, Non-Hodgkin
- Melanoma
- Mesothelioma
- Myelodysplastic Syndromes
- Neoplasms
- Pancreatic Neoplasms
- Primary Myelofibrosis
- Recurrence
- Salivary Gland Neoplasms
- Small Cell Lung Carcinoma
- Waldenstrom Macroglobulinemia
Recent trials (50)
- NCT05594758Lead sponsorN/A—
- NCT07178912CollaboratorPhase 2Feb 27, 2026
- NCT07282093Lead sponsorPhase 1Dec 31, 2025
- NCT06817720CollaboratorPhase 2Jul 30, 2025
- NCT06687070Lead sponsorPhase 1Nov 30, 2024
- NCT06640361Lead sponsorPhase 3Oct 31, 2024
- NCT06640361CollaboratorPhase 3Oct 31, 2024
- NCT06641414Lead sponsorPhase 3Oct 31, 2024
- NCT06401603CollaboratorPhase 1Aug 6, 2024
- NCT06389292Lead sponsorPhase 3Jun 11, 2024
- NCT06319456Lead sponsorPhase 3Apr 7, 2024
- NCT06423911Lead sponsorPhase 3Feb 5, 2024
- NCT06182969Lead sponsorPhase 1/Phase 2Dec 31, 2023
- NCT06104566Lead sponsorPhase 3Dec 20, 2023
- NCT06051409Lead sponsorPhase 3Sep 2, 2023
Details
- Founded
- Suzhou, CN Jun 1, 2009
- Last known activity
- Feb 27, 2026